Drug Profile


Alternative Names: 1083 17-1A; 17-1A; Adjuqual; C-1; CO17-1A; M-17-1A; Monoclonal antibody 17-1A; Panorex

Latest Information Update: 11 May 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Developer Ajinomoto; Centocor
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Colorectal cancer
  • No development reported Adenocarcinoma
  • Discontinued Pancreatic cancer

Most Recent Events

  • 20 Feb 2006 Discontinued - Phase-II for Colorectal cancer in Japan (IV-infusion)
  • 20 Feb 2006 No development reported - Clinical-Phase-Unknown for Adenocarcinoma in USA (IV-infusion)
  • 07 Oct 2003 Clinical trials in Adenocarcinoma in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top